It’s part of a new £50 million focus on stratified medicine looking at large groups of cancer patients to try and find ways of assessing which treatments cancers are likely to respond to and is one step towards ‘personalized medicine’.

The aim is to improve genetic testing in the UK’s National Health Service while collecting valuable research data. So, when personalized treatments targeting specific genes become available in the future, doctors will have access to the best possible tests to help them decide which cancer patients are suitable for these drugs and spare those who will not respond from having unnecessary treatment.

The first patient will be genetically tested in the first half of next year.

Read more about the multimillion pound project launched to improve genetic testing for cancer drugs.